AbbVie Inc (ABBV) : Piershale Financial Group scooped up 136 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 15, 2016. The investment management firm now holds a total of 532 shares of AbbVie Inc which is valued at $33,814.AbbVie Inc makes up approximately 0.02% of Piershale Financial Group’s portfolio.
Other Hedge Funds, Including , Gwm Advisors added ABBV to its portfolio by purchasing 7,324 company shares during the most recent quarter which is valued at $465,513. AbbVie Inc makes up approx 0.19% of Gwm Advisors’s portfolio.Gierl Augustine Investment Management Inc boosted its stake in ABBV in the latest quarter, The investment management firm added 2,645 additional shares and now holds a total of 46,558 shares of AbbVie Inc which is valued at $3,015,562. AbbVie Inc makes up approx 3.18% of Gierl Augustine Investment Management Inc’s portfolio.Nn Investment Partners Holdings N.v. reduced its stake in ABBV by selling 30,420 shares or 3.42% in the most recent quarter. The Hedge Fund company now holds 860,235 shares of ABBV which is valued at $55,717,421. AbbVie Inc makes up approx 0.51% of Nn Investment Partners Holdings N.v.’s portfolio.Douglass Winthrop Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 1,321 additional shares and now holds a total of 64,034 shares of AbbVie Inc which is valued at $4,147,482. AbbVie Inc makes up approx 0.30% of Douglass Winthrop Advisors’s portfolio.Svenska Handelsbanken Ab (publ) reduced its stake in ABBV by selling 547,365 shares or 98.35% in the most recent quarter. The Hedge Fund company now holds 9,200 shares of ABBV which is valued at $595,884. AbbVie Inc makes up approx 0.04% of Svenska Handelsbanken Ab (publ)’s portfolio.
AbbVie Inc opened for trading at $63.23 and hit $63.77 on the upside on Monday, eventually ending the session at $63.56, with a gain of 0.38% or 0.24 points. The heightened volatility saw the trading volume jump to 63,84,755 shares. Company has a market cap of $102,799 M.
On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.